Table 1 Select prospective trials that demonstrated improved outcomes for HPV-associated disease on unplanned retrospective subgroup analysis
From: De-intensification of adjuvant therapy in human papillomavirus-associated oropharyngeal cancer
Trial | Comparison arms | Finding (HPV+ improved outcomes) |
|---|---|---|
RTOG 0129 [44] | 70Â Gy over 7Â weeks vs 72Â Gy over 6Â weeks. Both arms included concurrent cisplatin | 8-years OS |
70.9% vs. 30.2% | ||
RTOG 0522 [45] | Concurrent radiation with cisplatin +/- cetuximab | 3-years OS |
85.6% vs. 60.1% | ||
ECOG 2399 [46] | Phase II trial: 2Â cycles of induction paclitaxel/carboplatin followed by radiation with concurrent paclitaxel | 2-years OS |
95% vs. 62% | ||
TROG 02.02 [47] | Radiation with concurrent cisplatin vs. radiation with concurrent cisplatin and tirapazamine | 2-years OS |
91% vs. 74% | ||
TAX 324 [48] | Induction docetaxel/cisplatin/fluorouracil followed by radiation with concurrent carboplatin vs. induction cisplatin/fluorouracil followed by radiation with concurrent carboplatin | 5-years OS |
82% vs. 35% |